Browsing by Author "Elena Navarro, Maria"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years
    (2019) Carrillo, Mitzy; Maturana, Gregorio; Maiz, Cristobal; Romero, Diego; Dominguez, Francisco; Oddo, David; Villarroel, Alejandra; Razmilic, Dravna; Elena Navarro, Maria; Leon, Augusto; Sanchez, Cesar; Camus, Mauricio
    Introduction: The optimal management of breast lesions with atypia (BLA), detected in percutaneous biopsies after screening mammograms, is a controversial issue. The aim of this paper is to compare histological diagnosis by percutaneous biopsy with the results of the surgical biopsy of these lesions and to analyse the changes to clinical approach this would imply.
  • No Thumbnail Available
    Item
    Surgical treatment in oligometastatic breast cancer
    (2019) Vargas, Catalina; Maiz, Cristobal; Elena Navarro, Maria; Oddo, David; Sanchez, Cesar; Bustos, Marisa; Camus, Mauricio
    Metastatic breast cancer (MBC) management is based on systemic treatment (ST), while the local therapy role remains controversial. We present the case of a 36-year-old woman with a diagnosis of hormone receptor-positive and human epidermal growth factor receptor type 2-positive breast cancer and isolated sternal metastasis, who received neoadjuvant ST with complete remission and later primary tumour surgery. Oligometastatic patients are a subgroup of MBC that can benefit from aggressive local therapies, even with curative intent.
  • No Thumbnail Available
    Item
    Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
    (2020) Sanchez, Cesar; Dominguez, Francisco; Galindo, Hector; Camus, Mauricio; Oddo, David; Villarroel, Alejandra; Razmilic, Dravna; Pena, Jose; Elena Navarro, Maria; Medina, Lidia; Merino, Tomas; Briones, Juan; Acevedo, Francisco
    Background: About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical presentation (stage IV, de novo disease at diagnosis versus systemic recurrence) and BC subtype on survival rates. Material and Methods: We evaluated 211 ER+ advanced BC (ABC) patients, treated between 1997 and 2017. Results: The median overall survival (OS) was 37 months. Median OS for the period 1997/2006 and 2007/2017 were 33 and 42 months, respectively (p = 0.47). Luminal A, ABC stage IV disease at diagnosis displayed better OS rates than Luminal B stage IV tumors (100 and 32 months respectively, p < 0.01). Conclusions: Clinical presentation (stage IV vs. systemic recurrence) and tumor subtype are key determinants of OS in ABC.